Structure guided inhibitor designing of CDK2 and discovery of potential leads against cancer

Journal of Molecular Modeling

Volumn 19, Issue 9, 2013, Pages 3581-3589

  V a, Arun Kumar ^a   Mohan, Keshav ^b   Riyaz, Syed ^c  

^a SATHYABAMA UNIVERSITY   (India)

^b SVN College of Engineering   (India)

^c GOKARAJU RANGARAJU INSTITUTE OF ENGINEERING AND TECHNOLOGY   (India)

Author keywords

CDK; HeLa; MCF 7; Pharmacophores

Indexed keywords

CYCLIN DEPENDENT KINASE 2 INHIBITOR;

ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER CELL CULTURE; CELL STRAIN MCF 7; CRYSTAL STRUCTURE; DRUG DESIGN; HELA CELL; HYDROGEN BOND; PHARMACOPHORE; PRIORITY JOURNAL; STATIC ELECTRICITY;

ANTINEOPLASTIC AGENTS; BENZOPYRANS; BINDING SITES; CELL LINE, TUMOR; CHEMISTRY, ORGANIC; CYCLIN-DEPENDENT KINASE 2; DRUG DISCOVERY; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; INDOLES; INHIBITORY CONCENTRATION 50; MCF-7 CELLS; MOLECULAR CONFORMATION; MOLECULAR DOCKING SIMULATION; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84882910840     PISSN: 16102940     EISSN: 09485023     Source Type: Journal    
DOI: 10.1007/s00894-013-1887-8     Document Type: Article

References (12)

1. Malumbres M, Barbacid M (2009) Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9:153-166
2. Chinni SR, Li Y, Upadhyay S, Koppolu PK, Sarkar FH (2001) Indole-3-carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells. Oncogene 20:2927-2936
3. Naik R, Nixon S, Lopes A et al (2006) A randomized phase II trials of indole-3-carbinol in the treatment of vulvar intraepithelial neoplasia. Int J Gynecol Cancer 16(2):786-790
4. Bell MC et al (2000) Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. Gynecol Oncol 78(2):123-129
5. Rampa A, Bisi A, Belluti F, Gobbi S, Piazzi L, Valenti P, Zampiron A, Caputo A, Varani K, Borea PA, Carrara M (2005) Homopterocarpanes as bridged triarylethylene analogues: synthesis and antagonistic effects in human MCF-7 breast cancer cells. Farmaco 60(2):135-147. doi: 10.1016/j.farmac.2004.09.006
6. Quan-Bin H, Nian-Yun Y, Hong-Lei T, Chun-Feng Q, Jing-Zheng S, Chang DC, Shi-Lin C, Luo KQ, Hong-Xi X (2008) Phytochemistry 69:2187
7. Coudert P, Coyquelet JM, Bastide J, Marion Y, Fialip J (1988) Ann Pharm Fr 46:91
8. Blundell TL (1996) Structure-based drug design. Nature 384(6604 suppl):23-26
9. Whittle PJ, Blundell TL (1994) Protein structure-based drug design. Annu Rev Biophys Biomol Struct 23:349
10. Kuntz ID (1992) Structure-based strategies for drug design and discovery. Science 257:1078
11. Halgren T (2009) Identifying and characterizing binding sites and assessing drug ability. J Chem Inf Model 49:377-389
12. Halgren T (2007) New method for fast and accurate binding-site identification and analysis. Chem Biol Drug Des 69:146-148